190 related articles for article (PubMed ID: 12105273)
1. HIV-1 matrix protein p17 increases the production of proinflammatory cytokines and counteracts IL-4 activity by binding to a cellular receptor.
De Francesco MA; Baronio M; Fiorentini S; Signorini C; Bonfanti C; Poiesi C; Popovic M; Grassi M; Garrafa E; Bozzo L; Lewis GK; Licenziati S; Gallo RC; Caruso A
Proc Natl Acad Sci U S A; 2002 Jul; 99(15):9972-7. PubMed ID: 12105273
[TBL] [Abstract][Full Text] [Related]
2. Preclinical studies on immunogenicity of the HIV-1 p17-based synthetic peptide AT20-KLH.
Fiorentini S; Marini E; Bozzo L; Trainini L; Saadoune L; Avolio M; Pontillo A; Bonfanti C; Sarmientos P; Caruso A
Biopolymers; 2004; 76(4):334-43. PubMed ID: 15386266
[TBL] [Abstract][Full Text] [Related]
3. HIV-1 matrix protein p17 enhances the proliferative activity of natural killer cells and increases their ability to secrete proinflammatory cytokines.
Vitale M; Caruso A; De Francesco MA; Rodella L; Bozzo L; Garrafa E; Grassi M; Gobbi G; Cacchioli A; Fiorentini S
Br J Haematol; 2003 Jan; 120(2):337-43. PubMed ID: 12542496
[TBL] [Abstract][Full Text] [Related]
4. Functions of the HIV-1 matrix protein p17.
Fiorentini S; Marini E; Caracciolo S; Caruso A
New Microbiol; 2006 Jan; 29(1):1-10. PubMed ID: 16608119
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 matrix protein p17 modulates in vivo preactivated murine T-cell response and enhances the induction of systemic and mucosal immunity against intranasally co-administered antigens.
Fiorentini S; Becker PD; Marini E; Marconi P; Avolio M; Tosti G; Link C; Manservigi R; Guzman CA; Caruso A
Viral Immunol; 2006; 19(2):177-88. PubMed ID: 16817760
[TBL] [Abstract][Full Text] [Related]
6. HIV p17 enhances lymphocyte proliferation and HIV-1 replication after binding to a human serum factor.
De Francesco MA; Caruso A; Fallacara F; Canaris AD; Dima F; Poiesi C; Licenziati S; Corulli M; Martinelli F; Fiorentini S; Turano A
AIDS; 1998 Feb; 12(3):245-52. PubMed ID: 9517986
[TBL] [Abstract][Full Text] [Related]
7. HIV p17 reverses the anti-inflammatory activity of IL-4 on IL-15 stimulated monocytes and modulates their ability to secrete MIP-1 alpha.
De Francesco MA; Poiesi C; Ricotta D; Manca N
Virus Res; 2006 Jun; 118(1-2):170-7. PubMed ID: 16427155
[TBL] [Abstract][Full Text] [Related]
8. HIV replication in IL-2-stimulated peripheral blood mononuclear cells is driven in an autocrine/paracrine manner by endogenous cytokines.
Kinter AL; Poli G; Fox L; Hardy E; Fauci AS
J Immunol; 1995 Mar; 154(5):2448-59. PubMed ID: 7868911
[TBL] [Abstract][Full Text] [Related]
9. cDNA encoding a single-chain antibody to HIV p17 with cytoplasmic or nuclear retention signals inhibits HIV-1 replication.
Tewari D; Goldstein SL; Notkins AL; Zhou P
J Immunol; 1998 Sep; 161(5):2642-7. PubMed ID: 9725267
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of HIV-1 replication in primary human T cells transduced with an intracellular anti-HIV-1 p17 antibody gene.
Tewari D; Notkins AL; Zhou P
J Gene Med; 2003 Mar; 5(3):182-9. PubMed ID: 12666184
[TBL] [Abstract][Full Text] [Related]
11. Characterization of recombinant influenza A virus as a vector for HIV-1 p17Gag.
de Goede AL; Boers PH; Dekker LJ; Osterhaus AD; Gruters RA; Rimmelzwaan GF
Vaccine; 2009 Sep; 27(42):5735-9. PubMed ID: 19647812
[TBL] [Abstract][Full Text] [Related]
12. HIV-1 p17 and IFN-gamma both induce fructose 1,6-bisphosphatase.
Besançon F; Just J; Bourgeade MF; Van Weyenbergh J; Solomon D; Guillozo H; Wietzerbin J; Cayre YE
J Interferon Cytokine Res; 1997 Aug; 17(8):461-7. PubMed ID: 9282826
[TBL] [Abstract][Full Text] [Related]
13. Interleukin-10-secreting CD4 cells from aged patients with AIDS decrease in-vitro HIV replication and tumour necrosis factor alpha production.
Andrade RM; Lima PG; Filho RG; Hygino J; Milczanowski SF; Andrade AF; Lauria C; Brindeiro R; Tanuri A; Bento CA
AIDS; 2007 Aug; 21(13):1763-70. PubMed ID: 17690575
[TBL] [Abstract][Full Text] [Related]
14. Neutralization of human immunodeficiency virus type 1 (HIV-1) with antibody from carriers' plasma against HIV-1 protein p17.
Kageyama S; Katsumoto T; Taniguchi K; Ismail SI; Shimmen T; Sasao F; Gao M; Owatari S; Wakamiya N; Tsuchie H; Ueda S; Shiraki K; Kurimura T
Acta Virol; 1996 Sep; 40(4):195-200. PubMed ID: 9014009
[TBL] [Abstract][Full Text] [Related]
15. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
Kang CY; Luo L; Wainberg MA; Li Y
Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
[TBL] [Abstract][Full Text] [Related]
16. Immunization of human HIV-seronegative volunteers with recombinant p17/p24:Ty virus-like particles elicits HIV-1 p24-specific cellular and humoral immune responses.
Martin SJ; Vyakarnam A; Cheingsong-Popov R; Callow D; Jones KL; Senior JM; Adams SE; Kingsman AJ; Matear P; Gotch FM
AIDS; 1993 Oct; 7(10):1315-23. PubMed ID: 8267904
[TBL] [Abstract][Full Text] [Related]
17. Recognition of two overlapping CTL epitopes in HIV-1 p17 by CTL from a long-term nonprogressing HIV-1-infected individual.
Harrer T; Harrer E; Barbosa P; Kaufmann F; Wagner R; Brüggemann S; Kalden JR; Feinberg M; Johnson RP; Buchbinder S; Walker BD
J Immunol; 1998 Nov; 161(9):4875-81. PubMed ID: 9794421
[TBL] [Abstract][Full Text] [Related]
18. HIV-1 matrix protein p17: a candidate antigen for therapeutic vaccines against AIDS.
Fiorentini S; Giagulli C; Caccuri F; Magiera AK; Caruso A
Pharmacol Ther; 2010 Dec; 128(3):433-44. PubMed ID: 20816696
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 p17 binds heparan sulfate proteoglycans to activated CD4(+) T cells.
Poiesi C; De Francesco MA; Baronio M; Manca N
Virus Res; 2008 Mar; 132(1-2):25-32. PubMed ID: 18036696
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens.
Kmieciak D; Bolesta E; Naito T; Gzyl J; Kaneko Y; Kozbor D
J Hum Virol; 2001; 4(6):306-16. PubMed ID: 12082397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
